Massive Pulmonary Embolism: Short-Term Effects of Thrombolytic Treatment

Grau, E.; Fontcuberta, J.; Pagé, M. A.; Martinez, R.; Félez, J.; Net, A.; Rutllant, M. LI.
November 1986
Angiology;Nov1986, Vol. 37 Issue 11, p832
Academic Journal
This study assessed the short-term effects of thrombolytic treatment in 38 patients with massive pulmonary embolism. Thirty-two were treated with streptokinase and six with urokinase. Intrapulmonary artery instillation of fibrinolytic agents was utilized except in 3 patients. There was a marked hemodynamic and arteriographic improvement (p< 0.0005) in 33 patients (86.8%). Four patients (10.5%) died because of treatment failure. In these cases the fibrinogen concentration remained above 1 gr/liter during therapy. Bleeding was detected in 22 patients (57.8%) but was most often related to puncture or cut-down sites, and only 2 patients (5.2%) had major bleeding. One patient (2.6%) had cerebral hemorrhage. It is concluded that "classic" thrombolytic treatment is to be chosen in life-threatening pulmonary embolism. However, the difficulties sometimes encountered in producing an intense lytic effect and its low fibrinolytic specificity for the thrombus do not permit the obtainment of better results.


Related Articles

  • THE ROLE OF IMAGING IN PULMONARY EMBOLISM OUTCOME. MATEI, RALUCA; MANIŢIU, IOAN // Acta Medica Transilvanica;mar2014, Vol. 19 Issue 1, p178 

    Pulmonary embolism (PE) is a pathology with still high mortality. Of the factors that influence natural evolution of PE, the most important is the degree of obstruction, hemodynamic status, the cardiopulmonar pre-existing status, length of thrombosis and spontaneous thrombolytic therapy of lungs...

  • Thrombolytic therapy for pulmonary embolism. Katchan, Brian M.; Katchan, B M // Canadian Journal of Surgery;Dec2000, Vol. 43 Issue 6, p411 

    Consensus regarding the use of thrombolysis to treat acute pulmonary embolism has not yet been reached. There is good evidence that thrombolytic agents dissolve clot more rapidly than heparin. However, proving that this benefit reduces the death rate from pulmonary embolism has been difficult....

  • Thrombolytic Therapy in Thrombosis: A National Institutes of Health Consensus Development Conference. Sherry, Sol; Bell, William R.; Duckert, F.H.; Fletcher, Anthony P.; Gurewich, Victor; Long, David M.; Marder, Victor J.; Roberts, Harold; Salzman, Edwin W.; Sasahara, Arthur; Verstraete, Marc // Annals of Internal Medicine;Jul80 Part 1, Vol. 93 Issue 1, p141 

    Editorial. Presents the consensus reached by a National Institutes of Health during a 1980 conference on thrombolytic therapy in thrombosis. Benefits for the use of thrombolytic therapy in acute deep-vein thrombosis and pulmonary embolism; Risks associated with the use of thrombolytic...

  • COMMENTARY: Persistent right ventricular dysfunction increased risk for recurrent venous thromboembolism after acute pulmonary embolism. Douketis, James; Kaatz, Scott // ACP Journal Club;Mar/Apr2007, Vol. 146 Issue 2, p46 

    The article presents the authors' views about a study which states that persistent right ventricular dysfunction (RVD) increased risk for recurrent venous thromboembolism (VTE) after acute pulmonary embolism (PE). Although the findings of the study has been associated with increased short-term...

  • THROMBOLYTIC THERAPY: DIFFERENCES BETWEEN STREPTOKINASE AND UROKINASE. Bell, William R. // Vascular Surgery;Nov/Dec1977, Vol. 11 Issue 6, p378 

    Compares the relative potency of streptokinase and urokinase as agents for thrombolytic therapy in patients with pulmonary emboli. Therapeutic regimens of streptokinase and urokinase; Biochemical properties of streptokinase and urokinase; Assessment of the therapeutic improvement after the...

  • Is Thrombolytic Therapy Effective for Pulmonary Embolism? Almoosa, Khalid // American Family Physician;3/15/2002, Vol. 65 Issue 6, p1097 

    Pulmonary embolism is a disorder that is associated with significant morbidity and mortality. Right-sided heart failure and recurrent pulmonary embolism are the main causes of death associated with pulmonary embolism in the first two weeks after the embolic event. Thrombolysis is a potentially...

  • EXPERIENCE WITH FIBRINOLYTIC THERAPY OF VASCULAR OCCLUSIVE DISEASE. Warner, W. L. // Vascular Surgery;Nov/Dec1977, Vol. 11 Issue 6, p364 

    1. There may well be a place for streptokinase therapy in selected patients with chronic arterial occlusion, but the emphasis should be on developing information on selection criteria. 2. Efficacy and safety have been established for the use of streptokinase in occluded AV cannulae, but this may...

  • THROMBOLYTIC TREATMENT WITH I.V. BRINASE OF ADVANCED ARTERIAL OBLITERATIVE DISEASE OF THE LIMBS. Lund, F.; Ekeström, S.; Frisch, E. P.; Magaard, F. // Angiology;Jul/Aug1975, Vol. 26 Issue 7, p534 

    The material includes 17 patients suffering from different degrees of chronic peripheral arterial disease (11 chronic patients stage III and IV. two patients with acute arterial occlusion, and four patients stage II). Presence and extent of arterial occlusion was ascertained by initial...

  • An Unusual Case of Pulmonary Embolism. Routledge, Tom; Jenkins, David // New England Journal of Medicine;4/14/2005, Vol. 352 Issue 15, p1578 

    The article presents the case of a 33-year-old woman with pulmonary embolism. She had dyspnea for six months with intermittent fever. She was admitted to a hospital with worsening hypoxia, dyspnea and patchy bilateral pulmonary consolidations. The condition of the patient worsened when treated...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics